These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 15082032)

  • 21. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.
    Dingemanse J; Wood N; Jorga K; Kettler R
    Br J Clin Pharmacol; 1997 Jan; 43(1):41-7. PubMed ID: 9056051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
    Stocchi F; Vacca L; Grassini P; De Pandis MF; Battaglia G; Cattaneo C; Fariello RG
    Neurology; 2006 Oct; 67(7 Suppl 2):S24-9. PubMed ID: 17030737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers.
    Jing S; Yuan Y; Leuratti C; Vaja V; Cattaneo C
    Clin Pharmacol Drug Dev; 2023 Nov; 12(11):1104-1113. PubMed ID: 37293981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
    Wasan H; Singh D; Kh R
    Brain Res Bull; 2021 Mar; 168():165-177. PubMed ID: 33387637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
    Stocchi F; Borgohain R; Onofrj M; Schapira AH; Bhatt M; Lucini V; Giuliani R; Anand R;
    Mov Disord; 2012 Jan; 27(1):106-12. PubMed ID: 21913224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.
    Leuratti C; Sardina M; Ventura P; Assandri A; Müller M; Brunner M
    Pharmacology; 2013; 92(3-4):207-16. PubMed ID: 24136086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safinamide in the treatment of Parkinson's disease.
    Schapira AH
    Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial.
    Stoltz M; Reynolds D; Elkins L; Salazar D; Weir S
    Clin Pharmacol Ther; 1995 Sep; 58(3):342-53. PubMed ID: 7554709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
    Abbruzzese G; Barone P; Lopiano L; Stocchi F
    Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
    Stocchi F; Torti M
    Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
    Perez-Lloret S; Rascol O
    Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
    Müller T; Riederer P; Grünblatt E
    Clin Neuropharmacol; 2017; 40(5):208-211. PubMed ID: 28682929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analgesic effect of safinamide mesylate in a rat model of neuropathic pain.
    Kogo Y; Koebis M; Kobayashi Y; Ishida T; Maeda T
    Behav Brain Res; 2023 Aug; 452():114555. PubMed ID: 37355233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safinamide for the treatment of Parkinson's disease.
    Dézsi L; Vécsei L
    Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
    Marquet A; Kupas K; Johne A; Astruc B; Patat A; Krösser S; Kovar A
    Clin Pharmacol Ther; 2012 Oct; 92(4):450-7. PubMed ID: 22948897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safinamide effect on sleep architecture of motor fluctuating Parkinson's disease patients: A polysomnographic rasagiline-controlled study.
    Bovenzi R; Conti M; Pierantozzi M; Testone G; Fernandes M; Manfredi N; Schirinzi T; Cerroni R; Mercuri NB; Stefani A; Liguori C
    Parkinsonism Relat Disord; 2024 Oct; 127():107103. PubMed ID: 39154406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safinamide: a new hope for Parkinson's disease?
    Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
    Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.